Cbio AS is developing novoleucel, a proprietary T-cell therapy that targets late-stage solid tumors by revitalizing immune cells to enhance their ability to combat oxidative stress. This approach aims to provide a potential cure for cancer patients who have exhausted other treatment options, with clinical trials set to begin at Karolinska Hospital in early 2025.
Funding
$4.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Late-stage solid tumors often develop resistance to conventional cancer treatments, leaving patients with limited options and a poor prognosis. The tumor microenvironment can suppress immune cell activity, hindering the body's natural ability to fight the cancer. Current T-cell therapies face challenges in effectively targeting and eradicating tumors while overcoming oxidative stress within the tumor microenvironment.
Solution
Cbio A/S is developing novoleucel, a T-cell therapy designed to address the unmet needs of patients with late-stage solid tumors. Novoleucel utilizes the REVITA technology platform to revitalize resting immune cells, arming them against oxidative stress and enhancing their ability to target and kill cancer cells. This approach aims to provide a broad-spectrum, multi-targeted T-cell product that can effectively track down and eradicate tumor cells, even in hostile conditions. By generating a broader T-cell repertoire with stemness-like properties, novoleucel reduces the likelihood of cancer escape and offers a potential cure for patients who have exhausted other treatment alternatives.
Target Audience
The primary target audience includes patients with late-stage solid tumors who have exhausted other treatment options, as well as oncologists and medical professionals seeking innovative immunotherapies.
Features
- REVITA technology platform for ex-vivo checkpoint inhibition and stimulation to generate a broader T-cell repertoire.
- Designed to revitalize resting immune cells and arm them against oxidative stress.
- Multi-targeted T-cell product for effective tracking and killing of cancer cells.
- Broad-spectrum T-cell therapy product designed to target and eradicate tumor cells.
- Manufacturing authorization to produce cell-based Advanced Therapy Medicinal Products (ATMPs) for clinical use.
- Cleanroom facilities with a current capacity to produce T-cell products for up to 150 patients per year.